Company / Free Cash Flow
BIOCRYST PHARMACEUTICALS INC Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$344.9M
FY2025
5-year range
-$163.2M / $344.9M
FY2021-FY2025
Trend
+749.0%
vs FY2024
Sector context
#27 of 194
Health Care
What the data says
Free Cash Flow changed +749% YoY in FY2025, a notable deviation from the 9-year average annual change of +75%.
Based on SEC 10-K filings.
$345M in FY2025. Top quartile in the Health Care sector.
Improved from -$97M to $345M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 194This company $344.9M Sector average $470.8M
▼
-26.7% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's free cash flow has grown for 3 consecutive years.
- In FY2025, free cash flow increased 749.0% year-over-year.
- Ranks #27 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $344.9M | +749.0% |
| FY2024 | -$53.1M | +45.4% |
| FY2023 | -$97.3M | +40.4% |
| FY2022 | -$163.2M | -12.9% |
| FY2021 | -$144.5M | -6.6% |
| FY2020 | -$135.6M | -50.8% |
| FY2019 | -$89.9M | +3.2% |
| FY2018 | -$92.9M | -124.1% |
| FY2017 | -$41.5M | +29.4% |
| FY2016 | -$58.7M | -221.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026